Rifampicin drug resistance and host immunity in tuberculosis: more than meets the eye.
Trends Immunol
; 44(9): 712-723, 2023 09.
Article
em En
| MEDLINE
| ID: mdl-37543504
ABSTRACT
Tuberculosis (TB) is the leading cause of death due to an infectious agent, with more than 1.5 million deaths attributed to TB annually worldwide. The global dissemination of drug resistance across Mycobacterium tuberculosis (Mtb) strains, causative of TB, resulted in an estimated 450 000 cases of drug-resistant (DR) TB in 2021. Dysregulated immune responses have been observed in patients with multidrug resistant (MDR) TB, but the effects of drug resistance acquisition and impact on host immunity remain obscure. In this review, we compile studies that span aspects of altered host-pathogen interactions and highlight research that explores how drug resistance and immunity might intersect. Understanding the immune processes differentially induced during DR TB would aid the development of rational therapeutics and vaccines for patients with MDR TB.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Tuberculose
/
Tuberculose Resistente a Múltiplos Medicamentos
/
Mycobacterium tuberculosis
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article